Loading...

Alexa Fluor® 488 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_Alexa488_071805
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Alexa Fluor® 488 (solid line) or rat IgG2a, κ Alexa Fluor® 488 isotype control (broken line).
  • 53-6.7_Alexa488_071805
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Alexa Fluor® 488 (solid line) or rat IgG2a, κ Alexa Fluor® 488 isotype control (broken line).
  • 53-6dot7_A488_CD8a_Antibody_2_092021.png
    Paraformaldehyde-fixed (1%), 500 µm-thick mouse thymus section was processed according to the Ce3D™ Tissue Clearing Kit protocol (Cat. No. 427701). The section was costained with anti-mouse CD8a Antibody (clone 53-6.7) Alexa Fluor® 488 at 5 µg/mL (green), anti-mouse CD3ε Antibody (clone 500A2) Alexa Fluor® 594 at 5 µg/mL (blue), and anti-mouse CD68 Antibody (clone FA-11) Alexa Fluor® 647 at 5 µg/mL (magenta). The section was then optically cleared and mounted in a sample chamber. The image was captured with a 10X objective using Zeiss 780 confocal microscope and processed by Imaris image analysis software.
    Watch the video.
Compare all formats See Alexa Fluor® 488 spectral data
Cat # Size Price Quantity Check Availability Save
100726 25 µg 36 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100723 100 µg 72 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
3D IHC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed
  2. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  3. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  4. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  5. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  6. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  7. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  8. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  9. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  10. Diamantopoulou Z, et al. 2022. Nature. 607:156. PubMed
  11. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  12. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  13. Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed
  14. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  15. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  16. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  17. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  18. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  19. Onishi S, et al. 2015. PLoS One. 10:126564. PubMed
  20. Tang B, et al. 2020. Clin Cancer Res. 26:2216. PubMed
  21. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  22. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  23. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  24. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  25. Yang H, et al. 2015. Cancer Res . 75: 3812-3822. PubMed
  26. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  27. Bartkowiak T, et al. 2015. Proc Natl Acad Sci U S A. 112: 5290-5299. PubMed
  28. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  29. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  30. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  31. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  32. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
  33. An J, et al. 2022. iScience. 25:103570. PubMed
  34. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  35. Yamada T, et al. 2016. J Immunol. 197: 4079 - 4089. PubMed
  36. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  37. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  38. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  39. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  40. Kim S, et al. 2021. Elife. 10:. PubMed
  41. Ma S, et al. 2022. Cell Rep. 38:110520. PubMed
  42. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  43. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  44. Collins N, et al. 2016. Nat Commun. 7:11514. PubMed
  45. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  46. Mantilla-Rojas C, et al. 2022. Cancers (Basel). 14:. PubMed
  47. Sun J, et al. 2020. Cell. 182:734. PubMed
  48. Lee C, et al. 2009. Clin Cancer Res. 2.538888889. PubMed
  49. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  50. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  51. Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed
  52. Kaddatz H, et al. 2020. Glia. 69:925. PubMed
  53. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  54. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  55. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  56. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  57. Zhu J et al. 2017. Cell stem cell. 20(3):374-384 . PubMed
  58. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  59. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  60. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  61. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  62. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  63. Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed
  64. Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
RRID
AB_389304 (BioLegend Cat. No. 100726)
AB_389304 (BioLegend Cat. No. 100723)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC,3D IHC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 5    Revision Date: 09.20.2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account